TerminatedPhase 1

Study Evaluating rhIL-11 in Left-Sided Ulcerative Colitis

Plain-language summary

To explore the safety of orally delivered rhIL-11 in patients with mild to moderate left-sided ulcerative colitis. To explore the effects of orally administered rhIL-11 on pharmacogenomics in blood samples and in colonic biopsy tissue samples.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Documented, signed informed consent to participate in this study * Age greater than or equal to 18 years * Documented diagnosis of ulcerative colitis by standard clinical criteria, including endoscopy (either flexible sigmoidoscopy or colonoscopy, sufficient to define the proximal limit of disease) with biopsy Exclusion Criteria: * Crohn's disease * Ulcerative proctitis * Ulcerative colitis extending beyond the splenic flexure

Trial details

NCT IDNCT00038922

SponsorWyeth is now a wholly owned subsidiary of Pfizer

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Ulcerative Colitis trials